Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia

Neurology

Volumn 50, Issue 5, 1998, Pages 1461-1463

  Brans, J W M ^a   Lindeboom, R ^a   Aramideh, M ^a   Speelman, J D ^a  

^a Department of Neurology ^*

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A;

ADULT; ARTICLE; CERVICAL SPINE; DRUG EFFECT; DYSTONIA; ELECTROMYOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; TORTICOLLIS;

EID: 0031867556     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.5.1461     Document Type: Article

References (8)

1. Lindeboom R, de Haan RJ, Aramideh M, Brans JWM, Speelman JD. Treatment outcomes in cervical dystonia: a clinimetric study. Mov Disord 1996;11:371-376.
2. Brans JWM, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology 1996;46: 1066-1072.
3. Tsui JKC, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2:245-246.
4. Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994:211-237.
5. Stewart AL, Hays RD, Ware JE. The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988;26:724-735.
6. Kazis L, Anderson J, Meenan R. Effect sizes for interpreting changes in health status measures. Med Care 1989;27(suppl 3):178-189.
7. Marion MH, Sheehy M, Sangla S, Soulayrol S. Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiatry 1995;59:102-103.
8. Brin MF, Blitzer A. Botulinum toxin: dangerous terminology errors. J R Soc Med 1993;86:493-494.